TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients
Moshe-Lilie O, Dimitrova D, Heitner S, Brannagan T, Zivkovic S, Hanna M, Masri A, Polydefkis M, Berk J, Gertz M, Karam C. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients. Amyloid 2020, 27: 250-253. PMID: 32578459, DOI: 10.1080/13506129.2020.1784134.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmyloid Neuropathies, FamilialDisease ProgressionFemaleGene SilencingHumansLiver TransplantationMaleMiddle AgedOligonucleotidesOligonucleotides, AntisensePrealbuminTreatment OutcomeConceptsHereditary transthyretin (TTR) amyloidosisGene silencing therapySilencing therapyMedian duration of therapyPatients stopped treatmentDuration of therapyATTR amyloidosis patientsBone marrow functionNeuropathy Impairment ScoreATTR amyloid depositsOrthotopic liver transplantationTTR gene silencingMedian durationMarrow functionMedian ageAmyloidosis patientsDiscontinued treatmentFrequent complicationMedian timeLiver rejectionLiver transplantationTreatment optionsDisease progressionGene silencing agentsPatients